BioSpace News Archive

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH).

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS).

Scopus BioPharma Inc. and its subsidiary, Duet BioTherapeutics Inc. announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.

Harpoon Therapeutics, Inc. announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma.

Standard BioTools Inc. today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation with a moderated Q&A session at the Jefferies London Healthcare Conference on Wednesday, November 15 at 11:00 a.m. GMT.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight ™ in Chronic Kidney Disease.

DifGen Pharmaceuticals LLC announced that it has successfully launched its second complex Transdermal product, generic Buprenorphine Transdermal System in the US market.

Smart Immune announced that a poster featuring SMART101, the first T cell progenitor therapy product in development from the Company’s ProTcell platform, will be presented at the American Society of Hematology Annual Meeting to be held 09-12 December 2023 in San Diego, California.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, announced the acceptance of an abstract for poster presentation at the upcoming 65th American Society of Hematology Annual Meeting and Exposition, being held from December 9–12, 2023, in San Diego, CA and online.